San Diego’s Illumina is the world leader in gene sequencing technology — the ability to read and record DNA. Now, the billion-dollar company is buying another in a bid to expand its portfolio in ...
Illumina's stock has rebounded 25% since October 2023, despite underwhelming revenue growth and challenges with the NovaSeq X platform and macro headwinds. The company faces issues with the adoption ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results